LAPTM4B and hepatocellular carcinoma: However, these patients are responsive to PD-L1 antibody therapy, highlighting sensitivity of LAPTM4B-overexpressing patients to targeted treatments and underscoring effectiveness of PD-L1 blockade on mitigating LAPTM4B overexpression-related effects in HCC.